首页 > 市场调查报告书 > 医疗设备

生技设备

市场调查报告书

商品编码

1624403

聚乙二醇化蛋白质市场规模（按地区、范围和预测）

PEGylated Proteins Market Size By Product, By Protein Type, By Application, By End-User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic Research Institutes), By Geographic Scope And Forecast

出版日期: 2024年07月31日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格

简介目录

聚乙二醇化蛋白质的市场规模及预测

聚乙二醇化蛋白质市场规模预计在 2023 年达到 13.4 亿美元，到 2031 年将达到 31.4 亿美元，2024 年至 2031 年的复合年增长率为 11.22%。聚乙二醇化蛋白质是透过在其表面附着聚乙二醇（PEG）链进行化学修饰的蛋白质。该过程涉及将 PEG 分子共价连接到蛋白质上的特定位置，从而影响溶解度、稳定性和药物动力学等特性。聚乙二醇化是生物製药中用于增强蛋白质药物治疗效果和安全性的典型技术。透过降低清除率、提高生物利用度和减少给药方案，PEG 链的加入可以增加蛋白质在血液中循环的时间。

此外，聚乙二醇化可以最大限度地降低免疫原性和蛋白水解的风险，并增强蛋白质疗法的稳定性和功效。该技术已应用于肿瘤学、血液学、免疫学和代谢疾病等各个医学领域，以创建生长因子、酵素、荷尔蒙和单株抗体等蛋白质类药物的长效製剂。

聚乙二醇化蛋白质的全球市场动态

主要市场驱动因子

提高功效和稳定性：

聚乙二醇化，即将聚乙二醇 (PEG) 链附着到蛋白质上，可显着提高蛋白质治疗的稳定性和溶解度。这种变化增加了药物的半衰期，降低了免疫原性并提高了生物利用度，使其更适合用于治疗。

慢性病发生率不断上升：

癌症、糖尿病和自体免疫疾病等慢性疾病的发生率不断上升，对有效治疗的需求也日益增长。因此，聚乙二醇化蛋白质由于其药物动力学改善和给药频率减少而越来越多地用于治疗这些疾病，从而推动了市场的成长。

药物传递技术的进步：

药物传递系统的技术进步有助于生产聚乙二醇化蛋白质，这些蛋白质可以更精确地针对特定的组织和器官，减少副作用并提高治疗效果。这正在加速个人化医疗的采用。

加强生物製药研发：

随着生物製药行业专注于创新生物製剂的研究和开发，聚乙二醇化正在被探索和利用来改进基于蛋白质的药物。对生物製药研发的资金和支持的增加正在推动聚乙二醇化蛋白质市场向前发展。

主要问题

开发及製造成本高：

蛋白质聚乙二醇化过程困难，需要大量的技术和经验投入，增加了开发和生产成本。这些增加的成本限制了市场准入和供应，阻碍了市场的成长。

潜在的免疫原性和安全性问题：

PEG化用于最大限度地降低免疫原性，但PEG分子本身可以在某些患者中引发免疫反应。解决这些安全问题并证明长期的有效性和安全性将为市场带来重大课题。

与替代药物输送系统的竞争：

脂质奈米颗粒和基于聚合物的系统等新型药物传输技术正在推动聚乙二醇化蛋白质市场的发展。这些替代技术在药物稳定性、疗效以及标靶分布等方面提供了类似甚至更好的优势，对聚乙二醇化蛋白质的优越性提出了课题。

主要趋势：

标靶药物传递的创新：

生产能够进行标靶药物输送的聚乙二醇化蛋白质的趋势日益增长。该方法旨在透过选择性地将药物输送到受损细胞来改善治疗效果，特别是在癌症和慢性病的治疗中，从而减少副作用并提高疗效。

扩展到罕见疾病：

聚乙二醇化蛋白质市场正在转向治疗罕见疾病和孤儿疾病。聚乙二醇化可改善药物动力学并降低免疫原性，使这些药物适合治疗替代疗法有限的罕见疾病。

合併治疗：

人们对聚乙二醇化蛋白质联合疗法的兴趣日益浓厚。这使得聚乙二醇化药物可以与其他治疗剂结合，以提高治疗效果，对抗抗药性，并为疾病管理提供全面的方法，特别是在癌症等复杂情况下。

聚乙二醇化技术的进展：

该领域正在不断改进聚乙二醇化方法，专注于实现聚乙二醇分子与蛋白质的位点特异性连接。这种精确度优化了药物的治疗效果，改善了患者的治疗效果并减少了副作用，从而实现了更有效、更安全的治疗。

PEGylated Proteins Market size was valued at USD 1.34 Billion in 2023 and is projected to reach USD 3.14 Billion by 2031, growing at a CAGR of 11.22% from 2024 to 2031. PEGylated proteins are those that have been chemically changed by adding polyethylene glycol (PEG) chains to their surfaces. This procedure includes covalently attaching PEG molecules to specific protein locations, affecting features like solubility, stability, and pharmacokinetics. PEGylation is a typical technique used in biopharmaceuticals to enhance the therapeutic efficacy and safety of protein medicines. The inclusion of PEG chains can increase protein circulation time in the bloodstream by lowering clearance rates, increasing bioavailability and allowing for fewer frequent dosage regimens.

Furthermore, PEGylation can also minimize immunogenicity and the risk of proteolytic degradation, increasing the stability and potency of protein therapies. This technology has been used in a variety of medical fields, including oncology, haematology, immunology, and metabolic disorders, to create long-acting formulations of protein-based drugs like growth factors, enzymes, hormones, and monoclonal antibodies.

Global PEGylated Proteins Market Dynamics

The key market dynamics that are shaping the PEGylated proteins market include:

Key Market Drivers

Enhanced Drug Efficacy and Stability:

PEGylation, which involves connecting polyethylene glycol (PEG) chains to proteins, significantly improves the stability and solubility of protein-based therapies. This change increases the drug's half-life, decreases immunogenicity, and improves bioavailability, boosting demand in therapeutic applications.

Growing Prevalence of Chronic Diseases:

The rising prevalence of chronic diseases such as cancer, diabetes, and autoimmune diseases has created a greater demand for effective treatment agents. As a result, PEGylated proteins are increasingly being used to treat these disorders due to their enhanced pharmacokinetics and lower dose frequency, propelling the market growth.

Advancements in Drug Delivery Technologies:

Technological advances in drug delivery systems have aided in the production of PEGylated proteins that may be targeted more accurately to specific tissues or organs, reducing side effects and enhancing therapeutic outcomes. This has accelerated their uptake in personalised medicine.

Increased Biopharmaceutical R&D:

PEGylation is being explored and used to improve the qualities of protein-based medicines as a result of the biopharmaceutical industry's increasing focus on the study and development of innovative biologics. Increased funding and support for biopharmaceutical R&D are propelling the PEGylated proteins market forward.

Key Challenges:

High Cost of Development and Production:

The process of PEGylating proteins is difficult and needs significant investment in technology and experience, which raises development and production costs. These increasing expenses limit accessibility and affordability, creating a barrier to market growth.

Potential Immunogenicity and Safety Concerns:

Even though PEGylation is utilized to minimize immunogenicity, the PEG molecule itself provokes immunological responses in certain patients. Addressing these safety issues and demonstrating long-term efficacy and safety pose considerable challenges for the market.

Competition from Alternative Drug Delivery Systems:

Emerging drug delivery technologies such as lipid nanoparticles and polymer-based systems are putting pressure on the PEGylated protein market. These alternatives provide comparable or superior benefits in terms of medication stability, effectiveness, and targeted distribution, challenging the dominance of PEGylated proteins.

Key Trends:

Targeted Drug Delivery Innovations:

There is a growing trend in producing PEGylated proteins capable of targeted medication delivery. This method strives to enhance therapeutic outcomes by directing the medicine selectively to damaged cells, lowering side effects and enhancing efficacy, especially in the treatment of cancer and chronic disorders.

Expansion into Rare Diseases:

The market for PEGylated proteins is shifting towards the treatment of rare and orphan diseases. PEGylation enhances pharmacokinetics and reduces immunogenicity, making these medicines good candidates for treating uncommon illnesses with limited therapy alternatives.

Combination Therapies:

There is increasing interest in utilizing PEGylated proteins in combination therapy. This entails combining PEGylated pharmaceuticals with other therapeutic agents to improve treatment efficacy, eliminate drug resistance, and give a comprehensive approach to illness management, particularly in complicated conditions such as cancer.

Advances in PEGylation Techniques:

The field is constantly improving PEGylation methods, with a focus on attaining site-specific attachment of PEG molecules to proteins. This precision optimizes the drug's therapeutic profile, improves patient outcomes, and reduces unwanted effects, resulting in more effective and safer treatments.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global PEGylated Proteins Market Regional Analysis

Here is a more detailed regional analysis of the PEGylated proteins market:

North America:

According to Verified Market Research, North America is estimated to dominate the PEGylated Proteins Market over the forecast period. North America, particularly the United States, has a highly developed healthcare system, with cutting-edge medical facilities and research organizations. This advanced infrastructure enables substantial research and development operations, resulting in the rapid advancement and implementation of PEGylated protein therapeutics.

The region is experiencing significant investments in biopharmaceutical research and development, led by both the public and commercial sectors. This financial support hastens the discovery of new PEGylated proteins, propelling North America forward in the worldwide market.

Furthermore, North America is home to many of the world's leading biotech and pharmaceutical businesses, which play an important role in the development and commercialization of PEGylated proteins. The region's market supremacy is due in large part to these companies' strategic concentration on PEGylation technologies.

Europe:

Europe's well-established healthcare infrastructure, which includes widespread access to healthcare services and high-quality medical facilities, promotes the acceptance and dissemination of novel treatments. The infrastructure also aids clinical trials and research, which improves the region's ability to develop and execute PEGylated protein therapeutics.

Investment in biopharmaceutical R&D is on the rise in Europe, due to both public and private funding. This financial support drives the discovery and development of new PEGylated protein medicines, which helps the region flourish in the market.

Furthermore, the European Medicines Agency (EMA) provides a cohesive regulatory framework for Europe, facilitating the approval and commercialization of sophisticated medicinal products such as PEGylated proteins. Also, some EU member states provide incentives for pharmaceutical research and innovation, thereby encouraging expansion in this sector.

Asia Pacific:

The Asia Pacific region's healthcare sector is rapidly expanding, driven by increased investments in healthcare infrastructure and a greater emphasis on modern medical treatments. This expansion promotes the use and integration of novel medicines, such as PEGylated proteins.

Chronic disease prevalence is increasing in Asia Pacific countries, with cancer, diabetes, and cardiovascular ailments being particularly common. This expanding disease burden increases the demand for effective and innovative treatments, with PEGylated proteins emerging as a possible answer due to their increased efficacy and lower adverse effects.

Furthermore, the region has emerged as a hotspot for pharmaceutical research and development, due to cheaper costs and a competent workforce. This environment promotes the creation and testing of PEGylated proteins, with backing from both domestic and international pharmaceutical businesses looking to capitalize on the burgeoning market.

Global PEGylated Proteins Market Segmentation Analysis

The PEGylated Proteins Market is segmented based on Product, Protein Type, Application, End-User and Geography.

PEGylated Proteins Market, By Product

Consumables
PEGylation Reagents
PEGylation Kits
Services

Based on the Product, the market is segmented into Consumables and Services. The consumables segment is estimated to dominate the PEGylated proteins market due to the vital role these consumables play in the PEGylation process, which improves the stability, solubility, and half-life of protein-based therapies. The consistent demand for these consumables at both the research and commercial production levels contributes greatly to their market dominance.

PEGylated Proteins Market, By Protein Type

Colony Stimulating Factors (CSFs)
Interferons
Erythropoietin
Monoclonal Antibodies
Recombinant Factor VIII
Others

Based on Protein Type, the market is segmented into Colony Stimulating Factors, Interferons, Erythropoietin, Monoclonal Antibodies, Recombinant Factor VIII and Others. The colony-stimulating factors (CSFs) segment is estimated to dominate the PEGylated proteins market due to its vital role in the treatment of neutropenia, a common side effect of chemotherapy, especially in cancer patients. CSFs are necessary for increasing the generation of white blood cells, which reduces the risk of infection in people with impaired immune systems. The discovery of PEGylated versions of CSFs has greatly enhanced clinical efficacy by prolonging their half-life, reducing dose frequency and increasing patient compliance.

PEGylated Proteins Market, By Application

Cancer Treatment
Hepatitis
Chronic Kidney Diseases
Hemophilia
Multiple Sclerosis
Gastrointestinal Disorders
Others

Based on Application, the market is segmented into Cancer Treatment, Hepatitis, Chronic Kidney Diseases, Hemophilia, Multiple Sclerosis, Gastrointestinal Disorders and Others. The cancer treatment segment is estimated to dominate the PEGylated proteins market due to the rising global cancer incidence and the urgent demand for effective treatments. PEGylated proteins have shown great promise in enhancing the efficacy and lowering the adverse effects of cancer medicines, making them an essential component of oncology therapy regimens. The targeted delivery properties of PEGylated proteins allow for the precision targeting of malignant cells while minimizing damage to healthy tissues and improving patient outcomes.

PEGylated Proteins Market, By End-User

Pharmaceutical & Biotechnology Companies
Contract Research Organizations (CROs)
Academic Research Institutes

Based on End-User, the market is divided into Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs) and Academic Research Institutes. The pharmaceutical & biotechnology companies segment is estimated to dominate the market over the forecast period due to their critical role throughout the whole lifetime of PEGylated proteins, from discovery and development to commercialization. These firms make major investments in research and development, fueling innovation in PEGylated protein therapeutics to meet unmet medical needs. Furthermore, they have the infrastructure, resources, and knowledge to traverse the complicated regulatory channels, enabling the successful market debut of these products.

PEGylated Proteins Market, By Geography

North America
Europe
Asia Pacific
Rest of the world

Based on Geography, the PEGylated proteins market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America is estimated to dominate the market during the forecasted period. North America, particularly the United States, has a well-developed healthcare infrastructure as well as a vibrant pharmaceutical research and development ecosystem, which is supported by major public and private sector investments. This region is home to some of the world's leading biopharmaceutical companies, which drive innovation in medication research, including the progress of PEGylated protein therapeutics. Furthermore, the presence of strong regulatory organizations such as the FDA assures that pharmaceutical products are of high quality and safe, encouraging more investment in the sector.

Key Players

The "PEGylated Proteins Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
Merck KGaA, F. Hoffmann-La Roche Ltd, Johnson & Johnson, Pfizer Inc., Novartis AG, Amgen Inc., Eli Lilly and Company, AbbVie Inc., Celgene Corporation, Samsung BioLogics Co., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Sanofi S.A., Bayer AG, AstraZeneca plc and Boehringer Ingelheim GmbH.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

In November 2022, Nektar Therapeutics made significant progress by presenting preclinical data for NKTR-288 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. NKTR-288, a PEG-conjugate of interferon-gamma (IFN-Y), intends to change IFN-Y binding to substrates and optimize the duration of IFN-Y signalling, with potential uses in oncology and infectious disorders.
In July 2022, Merck KGaA announced the purchase of Exelead, a biopharmaceutical CDMO that specializes in PEGylated pharmaceuticals and complicated injectable formulations, incorporating lipid nanoparticle (LNP)-based drug delivery technology. Merck KGaA's acquisition enhances its ability to provide novel PEGylated protein medicines.

1 INTRODUCTION OF GLOBAL PEGYLATED PROTEINS MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL PEGYLATED PROTEINS MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL PEGYLATED PROTEINS MARKET, BY END-USER

5.1 Overview
5.2 Pharmaceutical & Biotechnology Companies
5.3 Contract Research Organisations
5.4 Academic Research Institutes

6 GLOBAL PEGYLATED PROTEINS MARKET, BY APPLICATION

6.1 Overview
6.2 Cancer Treatment
6.3 Hepatitis
6.4 Chronic Kidney Disease
6.5 Hemophilia
6.6 Multiple Sclerosis
6.7 Gastrointestinal Disorder
6.8 Other

7 GLOBAL PEGYLATED PROTEINS MARKET, BY PRODUCT

7.1 Overview
7.2 Consumables
7.3 Services

8 GLOBAL PEGYLATED PROTEINS MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East and Africa

9 GLOBAL PEGYLATED PROTEINS MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 Merck Millipore
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Thermo Fisher Scientific Inc.
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 NOF American Corporation (A Subsidiary of NOF Corporation)
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Jenkem Technology
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Creative Pegworks
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Celares GmbH
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Quanta Biodesign, Ltd
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 Biomatrik, Inc.
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Iris Biotech GmbH
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 Laysan Bio, Inc.
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments

11 KEY DEVELOPMENTS

11.1 Product Launches/Developments
11.2 Mergers and Acquisitions
11.3 Business Expansions
11.4 Partnerships and Collaborations

12 Appendix

12.1 Related Research

02-2729-4219

+886-2-2729-4219

License/价格

聚乙二醇化蛋白质市场规模（按地区、范围和预测）

PEGylated Proteins Market Size By Product, By Protein Type, By Application, By End-User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic Research Institutes), By Geographic Scope And Forecast

聚乙二醇化蛋白质的市场规模及预测

聚乙二醇化蛋白质的全球市场动态

主要市场驱动因子

目录

第 1 章：全球聚乙二醇化蛋白质市场简介

第 2 章执行摘要

第 3 章：经过验证的市场研究方法

第 4 章 聚乙二醇化蛋白质的全球市场展望

5. 全球聚乙二醇化蛋白质市场（依最终用户划分）

6. 全球聚乙二醇化蛋白质市场（依应用）

7. 全球聚乙二醇化蛋白质市场（按产品）

8. 全球聚乙二醇化蛋白质市场（按地区）

第 9 章。 概述 各公司的市场排名 主要发展策略

第十章 公司简介

第 11 章 重大进展

第 12 章附录

PEGylated Proteins Market Size And Forecast